Who Uses Cosentyx Most Often?
Cosentyx (secukinumab), an IL-17A inhibitor, treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa in adults. Children aged 6 and older can receive it for moderate-to-severe plaque psoriasis weighing at least 50 kg.[1] Adults account for the vast majority of prescriptions, as these conditions typically onset in working-age adults (20s to 50s).
Which Age Group Shows Strongest Response Data?
Clinical trials demonstrate peak efficacy in adults 18-65. In psoriasis studies like ERASURE and FIXTURE, patients averaging 44-46 years achieved 80-90% PASI 75 response rates at week 12.[2] Psoriatic arthritis trials (FUTURE 1-5) enrolled adults up to age 65, with similar high response rates in those 40-60.[3] Older adults (>65) had lower enrollment and slightly reduced efficacy due to comorbidities, but still benefited.[4] Pediatric data from CAPS is limited to ages 6+, with 75% PASI 75 in moderate cases.[5]
Why Adults 40-60 Benefit Most
This group has the highest disease prevalence—psoriasis peaks at 45-64 years, psoriatic arthritis around 50, and axial spondyloarthritis in 30s-50s.[6] They face severe symptoms impacting work and quality of life, where Cosentyx reduces joint damage and skin clearance faster than alternatives like TNF inhibitors in head-to-head data.[7] Real-world registries confirm sustained benefits over 5 years in this cohort, with fewer discontinuations than in elderly patients.[8]
Pediatric Use and Limitations
Approved for kids 6+ with psoriasis (50+ kg), but not other indications. Trials show good short-term skin improvement, though long-term safety data is emerging. Younger children under 6 or lighter weights lack approval.[1]
Elderly Patients: Benefits vs Risks
Adults over 65 (about 10-15% of users) see efficacy but higher infection risks and slower response. Trials excluded severe cases, so real-world use requires caution with monitoring.[4]
How Efficacy Varies by Age in Trials
| Indication | Peak Age Response | Key Trial Data |
|------------|-------------------|---------------|
| Plaque Psoriasis | 40-60 | 85% PASI 90 at week 16[2] |
| Psoriatic Arthritis | 45-55 | 80% ACR20 at week 24[3] |
| Ankylosing Spondylitis | 40-50 | 60% ASAS40 at week 16[9] |
[1]: FDA Label for Cosentyx
[2]: Langley RG et al., N Engl J Med 2014
[3]: McInnes IB et al., Ann Rheum Dis 2015
[4]: Novartis safety data, EMA summary
[5]: Thaçi D et al., Lancet 2022
[6]: GBD Study 2019, Lancet
[7]: Baraliakos X et al., Lancet 2022 (MEASURE vs PREVENT)
[8]: Papp K et al., J Am Acad Dermatol 2021
[9]: Baeten D et al., Ann Rheum Dis 2015